Health Care - Spark Newswire

1 minute read

Caris Life Sciences Announced A Strategic Research Partnership With Incyte To Augment Precision Medicine Approaches For Incyte’s Oncology Pipeline; Deal Terms Not Disclosed

Today, 1:11 PM

Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs. For drug candidates developed under the

INCY

1 minute read

Why BioMarin Shares Are Plunging Today?

By Vandana Singh

Today, 1:11 PM

Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.

BBIO

1 minute read

Medtronic Says PulseSelect Ablation System Demonstrates ‘Impressive Results’

By Vandana Singh

Today, 1:11 PM

Medtronic plc (NYSE:MDT) announced that its PulseSelect Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse…

MDT

1 minute read

Clene’s Lead Amyotrophic Lateral Sclerosis Shows Improved Function, Slowed Disease Progression

By Vandana Singh

Today, 1:11 PM

Clene Inc (NASDAQ:CLNN) announced new results showing preserved ALS patient functional score (ALSFRS-R) and delayed time to clinical worsening from the…

CLNN

1 minute read

Investors Cheer Armata Pharma’s Encouraging Data From Lung Infection Candidate

By Vandana Singh

Today, 1:11 PM

Armata Pharmaceuticals Inc (NASDAQ:ARMP) announced positive topline results from the completed Phase 1b/2a SWARM-P.a. trial evaluating AP-PA02 for chronic pulmonary Pseudomonas aeruginosa infections in…

ARMP

1 minute read

BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study

By Vandana Singh

Today, 1:11 PM

BioCardia Inc (NASDAQ:BCDA) presented detailed echocardiography data from the roll-in cohort of the Phase 3 CardiAMP Cell Therapy Heart Failure Trial.…

BCDA

2 minute read

BridgeBio’s Dwarfism Candidate Shows Favorable Height Increase, Safety Profile

By Vandana Singh

Today, 1:11 PM

BridgeBio Pharma Inc (NASDAQ: BBIO) announced results from PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the fibroblast growth factor receptor.

BBIO

1 minute read

Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer’s Treatment

By Vandana Singh

Today, 1:11 PM

The FDA has accepted Eisai Co Ltd (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb) 100 mg/mL injection,…

BIIB

1 minute read

Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle

By Vandana Singh

Today, 1:11 PM

Cytokinetics Incorporated (NASDAQ:CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). At…

CYTK